Michael J Hall
Affiliation: Fox Chase Cancer Center
- Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients--will the ends justify the means?Michael J Hall
Medical Oncology and Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Natl Compr Canc Netw 8:606-11. 2010..Data supporting clinical efficacy (feasibility) and effectiveness (real-life performance) are critical before important policy changes are adopted, especially where issues of hereditary cancer risk and genetic privacy are involved...
- Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyondM J Hall
Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, United States Electronic address
Gynecol Oncol 140:565-74. 2016..Awareness of these new genes and the availability of new multi-gene panel tests is critical for providers on the front-line of women's health. ..
- Effects of a decision support intervention on decisional conflict associated with microsatellite instability testingMichael J Hall
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Cancer Epidemiol Biomarkers Prev 20:249-54. 2011....
- BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancerMichael J Hall
Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
Cancer 115:2222-33. 2009..In this study, the authors examined the prevalence of BRCA1 and BRCA2 mutations in an ethnically diverse group of women who were referred for genetic testing...
- Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testingMichael J Hall
Medical Oncology and Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Cancer Prev Res (Phila) 3:1579-85. 2010....
- Barriers to participation in cancer prevention clinical trialsMichael J Hall
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Acta Oncol 49:757-66. 2010..We sought to characterize barriers to prevention trial participation among medical oncologists and first-degree relatives of their patients...
- Significance of pathologic response to preoperative therapy in pancreatic cancerYun Shin Chun
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Ann Surg Oncol 18:3601-7. 2011..Pathologic response to preoperative therapy is increasingly recognized as an important prognostic factor in solid tumors. The impact of pathologic response on survival in pancreatic adenocarcinoma is not well established...
- Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancerAndrea D Forman
Familial Risk Assessment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Breast J 15:S56-62. 2009..g., medical mistrust, perceived disadvantages to genetic services), as well as additional barriers to care once mutation carriers are identified, will be reviewed...
- Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic AdenocarcinomaEfrat Dotan
From the Department of Medical Oncology, Protocol Support Laboratory, and Biostatistics Facility, Fox Chase Cancer Center, Philadelphia, PA South Jersey Regional Hospital, Vineland, NJ Clinical Trials Office, Fox Chase Cancer Center, Philadelphia, PA and Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
Pancreas 45:1131-5. 2016..In this pilot study, we isolated and phenotypically characterized circulating tumor cells (CTCs) from patients with metastatic pancreatic cancer and explored their relationship to clinical outcome...
- Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancerNamrata Vijayvergia
Department of Hematology and Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania
Cancer 122:3191-3198. 2016..The treatment of metastatic colorectal cancer (mCRC) has changed substantially in the last 2 decades, but to the authors' knowledge, the effect of age and comorbidities on chemotherapy use has not been well studied to date...
- Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessmentMichael J Hall
Department of Medicine, Columbia University College of Physicians and Surgeons, Mailman School of Public Health, New York, NY 10032, USA
J Genet Couns 17:365-72. 2008..In risk assessment for HBOS, identifying a family history of PC should strongly raise the suspicion of an unrecognized BRCA1/2 mutation...
- Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancerAlan A Thomay
Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
J Gastrointest Surg 18:69-74. 2014..In colorectal cancer, the involvement of regional lymph nodes with metastasis is an established prognostic factor. The impact of the number of positive nodes on patient outcome with stage IV disease is not well defined...
- Interpretation of genetic testing for lynch syndrome in patients with putative familial colorectal cancerChristina Rybak
Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA
J Natl Compr Canc Netw 9:1311-20. 2011..This article reviews important clinical features of LS genetic evaluation using 3 pedigree-based case examples from the Fox Chase Cancer Center Gastrointestinal Risk Assessment Clinic...
- Cost sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testingJennifer M Matro
Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA
J Genet Couns 23:1002-11. 2014..Identifying factors associated with willingness-to-pay for genetic services is increasingly important as testing is integrated into routine cancer care...
- Gene panel testing for inherited cancer riskMichael J Hall
From Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania Department of Internal Medicine, Division of Human Genetics, Ohio State University Comprehensive Cancer Center, Columbus, Ohio Clinical and Translational Hereditary Cancer Program, Vanderbilt Ingram Cancer Center, Nashville, Tennessee and Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
J Natl Compr Canc Netw 12:1339-46. 2014....
- Rates and predictors of colorectal cancer screening by race among motivated men participating in a Prostate Cancer Risk Assessment ProgramMichael J Hall
Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
Cancer 118:478-84. 2012..If present, such disparities could support hypotheses for further research examining racial differences in awareness and patient preferences in undergoing CRC screening...
- Disparities in genetic testing: thinking outside the BRCA boxMichael J Hall
Department of Medicine, Mailman School of Public Health, Columbia University, New York, NY, USA
J Clin Oncol 24:2197-203. 2006..The importance of expanded testing in underserved populations is emphasized...
- Defining venous involvement in borderline resectable pancreatic cancerYun Shin Chun
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Ann Surg Oncol 17:2832-8. 2010..There is no consensus about what degree of venous impingement constitutes borderline resectability...
- Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancerEfrat Dotan
Fox Chase Cancer Center, Philadelphia, PA and University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
J Oncol Pract 10:308-14. 2014..Little is known about prescribers' response to new clinical data, practice guidelines, and US Food and Drug Administration (FDA) label change with regard to the use of anti-EGFR antibodies in clinical practice...
- Understanding patient and provider perceptions and expectations of genomic medicineMichael J Hall
Fox Chase Cancer Center, Philadelphia, Pennsylvania
J Surg Oncol 111:9-17. 2015..Their experiences will frame a discussion about how current testing may challenge patient understanding and expectations toward the evaluation of cancer risk and downstream preventive behaviors...
- Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancerDawn Hershman
Department of Medicine, Mailman School of Public Health, Columbia University, New York, New York, USA
Cancer 107:2581-8. 2006..However, to the authors' knowledge, the effect of the interval between surgery and the initiation of chemotherapy on survival has not been investigated...